Eli Lilly to acquire AtaiBeckley in $2.8 billion deal, offering $6.75 per share plus potential milestones

Eli Lilly and Co. has agreed to buy AtaiBeckley in a deal valued at $2.8 billion, a report said on Thursday, as the drugmaker looks to expand its pipeline and deal-making momentum. The transaction would be structured as an all-cash offer at $6.75 per share, plus additional milestone payments that could raise the total value of the acquisition.

Under the terms described in the report, Lilly would pay $6.75 a share in cash to AtaiBeckley shareholders. The proposal also includes up to $1 billion in milestone payments, which would be paid only if certain future objectives are met, such as progress related to specific programs or development milestones.

The milestone component is designed to align incentives across development stages, a common structure in biotechnology deals where the future value depends on clinical outcomes and regulatory or commercial progress. If those targets are not achieved, the additional payments may never be triggered, which affects the ultimate cost and risk profile of the acquisition.

AtaiBeckley, which the report frames as a target in the transaction, has been the subject of investor focus around the prospect that Lilly would incorporate its assets into a broader Lilly development plan. The deal headline suggests Lilly views the portfolio as strategically useful enough to justify an immediate cash premium, plus upside tied to performance.

For Lilly, acquisitions like this can be a way to add or accelerate drug candidates without waiting for early-stage research to mature inside the company. At a time when many large pharmaceutical firms are balancing patent-expiration pressures with pipeline renewal, M&A remains one of the fastest ways to secure additional development-stage assets.

The report did not provide detailed information on which specific AtaiBeckley programs are included in the purchase, the timing of any expected regulatory approvals, or how the milestone targets are calculated. It also did not outline whether the offer requires shareholder approval from AtaiBeckley or what conditions could delay or block the closing.

What remains unclear, based on the information available in the reported deal description, is how the milestone milestones are tied to measurable outcomes, such as clinical trial readouts or regulatory filings, and whether those thresholds are based on product performance in specific indications. Those details matter because they determine how much additional value the target company could earn and how much contingency is embedded in the economics of the purchase.

Investors will likely watch for further disclosures that typically accompany acquisitions of this type, including the formal offer documentation, the list of assets being acquired, and the conditions for completing the transaction. Any updates on the milestone framework, combined with timelines for closing and integration, could also influence how the market prices the probability of full deal completion.